Laurus Labs Ltd
P&L
Quarterly Consolidated
vs Q2 FY25
Laurus Labs Reports Q3 & 9M FY25 Results: Revenues at INR 1,415 Cr and INR 3,834 Cr; EBITDA at INR 285 Cr and INR 638 Cr
24 Jan 2025 · 24 Jan 2025, 08:51 pm
Summary
Laurus Labs, a leading research and development driven pharmaceutical and biotech company in India, has announced its Q3 & 9M FY25 results. The company reported revenues of INR 1,415 Cr for Q3 FY25, a growth of 18% Y-o-Y, and INR 3,834 Cr for 9M FY25, a growth of 6% Y-o-Y. The EBITDA for Q3 FY25 stood at INR 285 Cr, a growth of 56% Y-o-Y, and INR 638 Cr for 9M FY25, a growth of 18% Y-o-Y. The company's gross margins remained healthy at 56.9% for Q3 FY25 and 55.8% for 9M FY25.
Key Highlights
- 1
9M Revenues of INR 3,834 Cr and 6% revenue growth, performance on track to deliver Full Year growth outlook with Q4 revenues accelerating on planned project deliveries
- 2
3Q FY25 revenues of INR 1,415 Cr; +18% revenue growth, INR 285 Cr EBITDA; +56% growth resulted in a margin of 20.1%
- 3
Strengthening operational performance in CMO/CDMO with continued demand for complex API capabilities
- 4
CAPEX investments in key growth projects are on track to support long term growth
- 5
FY 2025 outlook retained; Revenue growth and EBITDA margins improvement, led by execution on few late-phase clinical projects along with reduction in net debt
Management Comments
Dr. Satyanarayana Chava
Founder & Chief Executive Officer
Q3 operating performance has improved progressively; we have delivered healthy growth, driven by growing demand for our platform capabilities, effectively addressing evolving customer needs. The quarter witnessed robust growth in the CDMO and FDF division, partially offset by soft API performance. Healthy commercial execution is our top priority and our performance is well on track with revenues accelerating in Q4.
V V Ravi Kumar
Executive Director & Chief Financial Officer
We are pleased to report healthy progress for the quarter; we delivered INR 1,415 Cr in revenues, strong growth of 18% and INR 285 Cr EBITDA grew by 56%, resulting in 20.1% margin. Gross margins remained healthy at 56.9% due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy, driven by order book position and continued progress in CDMO projects.
Informational and educational content only. Not investment advice.